5262-63-5

Basic information

• Product Name: Benzothiazole, 2,4-dimethyl- (6CI,7CI,8CI,9CI)
• Synonyms: Benzothiazole, 2,4-dimethyl- (6CI,7CI,8CI,9CI);2,4-Dimethylbenzothiazole;2,4-DiMethylbenzo[d]thiazole;2,4-Dimethyl-benzthiazol
• CAS NO: 5262-63-5
• Molecular Formula: C9H9NS
• Molecular Weight: 163.243
• Product Categories: BENZOTHIAZOLE
• Mol File: 5262-63-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 259.4 °C at 760 mmHg
• Flash Point: 112.7 °C
• Appearance: /
• Density: 1.176 g/cm³
• Vapor Pressure: 0.021mmHg at 25°C
• Refractive Index: 1.643
• CAS DataBase Reference: Benzothiazole, 2,4-dimethyl- (6CI,7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzothiazole, 2,4-dimethyl- (6CI,7CI,8CI,9CI)(5262-63-5)
• EPA Substance Registry System: Benzothiazole, 2,4-dimethyl- (6CI,7CI,8CI,9CI)(5262-63-5)

Safety Data

• Hazardous Substances Data: 5262-63-5(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

2,4-Dimethyl-benzothiazole, is used in the preparation of quaternary salts of chalcogenites as photographic sensitizers.

InChI:InChI=1/C9H9NS/c1-6-4-3-5-8-9(6)10-7(2)11-8/h3-5H,1-2H3

Upstream product

• 5304-37-0 (4-methyl-benzothiazol-2-yl)-malonic acid diethyl ester 
• 141-82-2 malonic acid 
• 614-69-7 2-tolyl isothiocyanate 
• 3288-01-5 diethyl N-(2-methylphenyl)thiocarbamoylmalonate 
• 35274-15-8 N-(2-methylphenyl)ethanethioamide 
• 996-82-7 sodium diethylmalonate 
• 622-59-3 1-isothiocyanato-4-methylbenzene 

Downstream Products

• 112991-36-3 3-ethyl-2-(4-dimethylamino-styryl)-4-methyl-benzothiazolium; iodide 

Relevant articles and documents

RODENTIA ANIMAL REPELLENT

PROBLEM TO BE SOLVED: To provide a repellent having a superior repellent activity for Rodentia animals, and a repellent method for Rodentia animals. SOLUTION: A Rodentia animal repellent contains, as an active ingredient, a compound represented by the for

ANTI-CANCER COMPOUNDS

Provided are methods and compositions for the treatment of diseases such as cancer. In certain aspects, compounds which can inhibit Skp2 are provided. Specifically chromenone derivatives are disclosed that have the capability toward reducing differentiation of pluripotent, multipotent or totipotent cells and thus have therapeutic utility in the treatment of a proliferative disease such as cancer.